Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19441066 | 0.98 | FDPS (0.39) | OPRM1FDPSLMNADNM1MAPT | |
| SCHEMBL24368316 | 0.98 | FDPS (0.39) | OPRM1FDPSLMNADNM1MAPT | |
| SCHEMBL24486038 | 0.98 | FDPS (0.39) | OPRM1FDPSLMNADNM1MAPT | |
| SCHEMBL2872599 | 0.95 | L3MBTL1 (0.38) | OPRM1FDPSLMNAHRH3L3MBTL1 | |
| SCHEMBL24688643 | 0.93 | HRH3 (0.40) | OPRM1FDPSLMNAHRH3L3MBTL1 | |
| SCHEMBL14127423 | 0.93 | FDPS (0.39) | OPRM1FDPSLMNAHRH3L3MBTL1 | |
| SCHEMBL3160023 | 0.93 | HRH3 (0.40) | OPRM1FDPSLMNAHRH3L3MBTL1 | |
| SCHEMBL23251113 | 0.93 | FDPS (0.39) | OPRM1FDPSLMNAHRH3L3MBTL1 | |
| SCHEMBL2228223 | 0.93 | FDPS (0.39) | OPRM1FDPSLMNAHRH3L3MBTL1 | |
| SCHEMBL12469943 | 0.93 | FDPS (0.39) | OPRM1FDPSLMNAHRH3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066636-B1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-26 | — | — | EP | disclosed |
| EP-1896445-B1 | ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | disclosed |
| EP-1812418-B1 | DIBENZOSUBERONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-7786128-B2 | Indole or benzimidazole derivatives as CB1 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1716132-B1 | SPIRO-BENZODIOXOLES AND THEIR USE AS CB1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-25 | — | — | EP | disclosed |
| US-7781593-B2 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100056513-A1 | STEREOSPECIFICALLY SUBSTITUTED BENZO[1,3]DIOXOLYL DERIVATIVES | FREI BEAT | 2010-03-04 | — | — | US | disclosed |
| US-7629346-B2 | Pyrazinecarboxamide derivatives as CB1 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1583742-B1 | CB 1 RECEPTOUR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-12-02 | — | — | EP | disclosed |
| US-7579369-B2 | CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| WO-2005058887-A1 | NOVEL THIAZOLE DERIVATES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-6900227-B2 | Benzodioxole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1532132-A1 | NOVEL BENZODIOXOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005000301-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266845-A1 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. | 2004-12-30 | — | — | US | disclosed |
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | HOFFMANN-LA ROCHE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004060888-A1 | NOVEL CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-20040142922-A1 | Benzodioxole derivatives | HOFFMANN-LA ROCHE INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004013120-A1 | NOVEL BENZODIOXOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167129-A1 | Novel CB 1 receptor inverse agonists | CNR1, CNR2, ARRB1 | OPRM1 17/4885FDPS 3962/4885LMNA 3407/4885 |
| US-20040142922-A1 | Benzodioxole derivatives | CNR1, CNR2, GPR119 | OPRM1 85/4885FDPS 1944/4885LMNA 4186/4885 |
| US-20040266845-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | OPRM1 33/4885FDPS 3230/4885LMNA 4004/4885 |
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | CNR1, CNR2, NPY1R | OPRM1 145/4885FDPS 1970/4885LMNA 4423/4885 |
| US-20100056513-A1 | STEREOSPECIFICALLY SUBSTITUTED BENZO[1,3]DIOXOLYL DERIVATIVES | CNR1, CNR2, NPY1R | OPRM1 14/4885FDPS 1972/4885LMNA 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.